LUMASON®
(sulfur hexafluoride lipid-type A microspheres)
for injectable suspension, for intravenous use or intravesical use

Ultrasound

Raise the standard for echocardiographic images above suboptimal[1]

KNOW NOW

with LUMASON®
Ultrasound Contrast



The ultrasound contrast agent LUMASON helps improve image quality at the point of patient care.

Echocardiographic images shown are representative images from reference studies. Individual results may vary.

Committed **to Science,**
Committed **to You.**™

BRACCO
LIFE FROM INSIDE

LUMASON®
(sulfur hexafluoride lipid-type A microspheres)
for injectable suspension, for intravenous use or intravesical use

RESPOND NOW TO SUBOPTIMAL IMAGES

Make a visible difference with LUMASON.[1]

UNENHANCED ECHO

LUMASON ECHO

Echocardiographic images are courtesy of Stephen Glen, Forth Valley Royal Hospital, Larbert, United Kingdom.
Individual results may vary.

INDICATIONS AND USAGE[1]

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS[1]

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION[1]

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres *[see Warnings and Precautions (5.1)]*. Most serious reactions occur within 30 minutes of administration *[see Warnings and Precautions (5.1)]*.

- **Assess all patients for the presence of any condition that precludes administration *[see Contraindications (4)]*.**
- **Always have resuscitation equipment and trained personnel readily available *[see Warnings and Precautions (5.1)]*.**

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) *[see Warnings and Precautions (5.1)]*.[1]

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed **WARNING** at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.

Committed **to Science,**
Committed **to You.**™

BRACCO
LIFE FROM INSIDE

LUMASON®
(sulfur hexafluoride lipid-type A microspheres)
for injectable suspension, for intravenous use or intravesical use

ENHANCE

LUMASON improves echo quality by **delineating the endocardial border**[1]

OPACIFY

LUMASON improves echo quality by **opacifying the left ventricular chamber**[1]



KNOW NOW

At Bracco, we are committed to raising the standard for echocardiographic images above suboptimal.[1]

Echocardiographic images shown are representative images from reference studies. Individual results may vary.

INDICATIONS AND USAGE[1]

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS[1]

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION[1]

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres *[see Warnings and Precautions (5.1)]*. Most serious reactions occur within 30 minutes of administration *[see Warnings and Precautions (5.1)]*.

- **Assess all patients for the presence of any condition that precludes administration *[see Contraindications (4)]*.**
- **Always have resuscitation equipment and trained personnel readily available *[see Warnings and Precautions (5.1)]*.**

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) *[see Warnings and Precautions (5.1)]*.[1]

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed **WARNING** at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.

Committed **to Science,**
Committed **to You.**™

BRACCO
LIFE FROM INSIDE

LUMASON®
(sulfur hexafluoride lipid-type A microspheres)
for injectable suspension, for intravenous use or intravesical use

IMAGE NOW WITH PROVEN EFFICACY AND SAFETY

LUMASON helped enhance image quality by improving **endocardial border delineation**[1†]



UNENHANCED ECHO



LUMASON ECHO

LUMASON resulted in reduction in percentage of patients with inadequate border delineation.[1]

Echocardiographic images are courtesy of Nicola Gaibazzi, Cardiology Department, Parma University Hospital, Parma, Italy.
Individual results may vary.

Administration of LUMASON **improved left ventricular border delineation.**[1†]

†Study design: Efficacy was established in 3 multicenter, controlled clinical trials evaluating endocardial border delineation and duration of useful contrast effect in patients with suspected cardiac disease and suboptimal noncontrast echocardiograms. LUMASON resulted in reduction in percentage of patients with inadequate border delineation.

INDICATIONS AND USAGE[1]

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS[1]

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION[1]

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres *[see Warnings and Precautions (5.1)]*. Most serious reactions occur within 30 minutes of administration *[see Warnings and Precautions (5.1)]*.

- **Assess all patients for the presence of any condition that precludes administration *[see Contraindications (4)]*.**
- **Always have resuscitation equipment and trained personnel readily available *[see Warnings and Precautions (5.1)]*.**

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) *[see Warnings and Precautions (5.1)]*.[1]

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed **WARNING** at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.

Committed **to Science,**
Committed **to You.**™

BRACCO
LIFE FROM INSIDE

LUMASON®
(sulfur hexafluoride lipid-type A microspheres)
for injectable suspension, for intravenous use or intravesical use

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In the LUMASON completed clinical trials, 6856 adult patients were exposed to LUMASON; the most commonly reported adverse reactions (occurring in at least 0.2% of patients) are listed below.

Adverse Reactions in Patients* (n=6856)[1]

Number (%) of Patients with Adverse Reactions	Headache	Nausea	Dysgeusia	Injection-site pain	Feeling hot	Chest discomfort	Chest pain	Dizziness	Injection-site warmth
340 (5%)	65 (1%)	37 (0.5%)	29 (0.4%)	23 (0.3%)	18 (0.3%)	17 (0.2%)	12 (0.2%)	11 (0.2%)	11 (0.2%)

*occurring in at least 0.2% of patients

Most adverse reactions were mild to moderate in intensity and resolved spontaneously.[1]

LUMASON is an ultrasound contrast agent made up of SF_6-filled microspheres.
LUMASON is not chemically related to sulfonamide antibiotics.[1]

Sulfur hexafluoride gas in LUMASON is inert and undergoes little or no biotransformation[1]

LUMASON microspheres are constructed of sulfur hexafluoride gas in a highly elastic shell[2]

- ≥99% of LUMASON microspheres are ≤10 µm[1]
  - Upper size limit: 100% of LUMASON microspheres are ≤20 µm[1]
- Designed to be stable and resist pressure changes[2]
- Acoustic properties constant over the entire range of frequencies used in clinical settings[3]

Small **spheres** make a big difference



LUMASON is known globally as SonoVue® which has been administered to millions of patients worldwide since its first approval in 2001.[4]

The individuals who appear are for illustrative purposes only. All persons depicted are models and not real patients or healthcare professionals.

INDICATIONS AND USAGE[1]

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS[1]

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION[1]

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres *[see Warnings and Precautions (5.1)]*. Most serious reactions occur within 30 minutes of administration *[see Warnings and Precautions (5.1)]*.

- **Assess all patients for the presence of any condition that precludes administration *[see Contraindications (4)]*.**
- **Always have resuscitation equipment and trained personnel readily available *[see Warnings and Precautions (5.1)]*.**

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) *[see Warnings and Precautions (5.1)]*.[1]

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed **WARNING** at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.

Committed **to Science,**
Committed **to You.**™

BRACCO
LIFE FROM INSIDE

LUMASON®
(sulfur hexafluoride lipid-type A microspheres)
for injectable suspension, for intravenous use or intravesical use

ADMINISTER—IN VARIOUS CLINICAL SETTINGS

Portable kit

- Single patient-use procedural kit[1]
- Simple-to-use
  - Shake vigorously for 20 seconds until homogeneous white milky liquid forms
  - No activation device required

1 LUMASON Vial

2 Mini-spike

3 Prefilled syringe containing 5 mL Sodium Chloride 0.9% injection, USP (diluent)[1]



Safe and effective in patients like those you care for every day[1]

Among ultrasound contrast
Only LUMASON does not require refrigeration

INDICATIONS AND USAGE[1]

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS[1]

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION[1]

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres *[see Warnings and Precautions (5.1)]*. Most serious reactions occur within 30 minutes of administration *[see Warnings and Precautions (5.1)]*.

- **Assess all patients for the presence of any condition that precludes administration *[see Contraindications (4)]*.**
- **Always have resuscitation equipment and trained personnel readily available *[see Warnings and Precautions (5.1)]*.**

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) *[see Warnings and Precautions (5.1)]*.[1]

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed **WARNING** at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.

Committed **to Science,**
Committed **to You.**™

BRACCO
LIFE FROM INSIDE

LUMASON®
(sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use

BRACCO SUPPORT—YOUR INSIGHT, OUR SOLUTIONS

Products and programs from a global leader in contrast imaging solutions

Dedicated Clinical Applications Team
Supports clinicians, educational programs, and product evaluations

Dedicated Account Managers
Focus on the clinical and economic value of LUMASON

Medical Education
Peer-to-peer and from internal Bracco medical staff

Corporate Investment and Resources
Support societies and the ultrasound imaging community

New Technology Reimbursement
LUMASON is the only agent with a dedicated pass-through code:
https://www.braccoimaging.com/sites/braccoimaging.com/files/technica_sheet_pdf/us-en-2018-01-30-reimbursement-kit-lumason.pdf

Dedicated Reimbursement Hotline
For ongoing reimbursement assistance:
Call **1-800-349-1388** or email **askbracco@reimbursement.bracco.com**

At Bracco Diagnostics Inc.,
Your Insight,
Our Solutions

The individuals who appear are for illustrative purposes only. All persons depicted are models and not real patients or healthcare professionals.

INDICATIONS AND USAGE[1]
LUMASON is an ultrasound contrast agent indicated for use:
- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS[1]
LUMASON is contraindicated in patients with:
- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION[1]

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres *[see Warnings and Precautions (5.1)]*. Most serious reactions occur within 30 minutes of administration *[see Warnings and Precautions (5.1)]*.
- **Assess all patients for the presence of any condition that precludes administration *[see Contraindications (4)]*.**
- **Always have resuscitation equipment and trained personnel readily available *[see Warnings and Precautions (5.1)]*.**

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) *[see Warnings and Precautions (5.1)]*.[1]

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed **WARNING** at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.

Committed **to Science,**
Committed **to You.**™

BRACCO
LIFE FROM INSIDE

LUMASON®

(sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use



KNOW **NOW**

with LUMASON Ultrasound Contrast

Echocardiographic images shown are representative images from reference studies. Individual results may vary.

LUMASON helps you obtain quality diagnostic images at the point of patient care

- Image quality[1]
- Proven safety and efficacy profile[1]
- Portable kit[1]
- No refrigeration or activation devices required[1]
- Support from Bracco Diagnostics Inc.—the company that understands your contrast imaging needs

Ordering Information

NDC#	0270-7099-16
Product description	LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, 25 mg/vial
Packaging	5 kits per carton

Customer Service: 1-877-BRACCO 9 (1-877-272-2269)

References: 1. LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; December 2016. **2.** Schneider M. Characteristics of SonoVue. *Echocardiography*. 1999;16(7, pt 2):743-746. **3.** Schneider M, Arditi M, Barrau MB, et al. BR1: A new ultrasonographic contrast agent based on sulfur hexaflouride-filled microbubbles. *Invest Radiol.* 1995;30(8):451-457. **4.** Data on file. Bracco Diagnostics Inc.

INDICATIONS AND USAGE[1]

LUMASON is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS[1]

LUMASON is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION[1]

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres *[see Warnings and Precautions (5.1)]*. Most serious reactions occur within 30 minutes of administration *[see Warnings and Precautions (5.1)]*.

- **Assess all patients for the presence of any condition that precludes administration *[see Contraindications (4)]*.**
- **Always have resuscitation equipment and trained personnel readily available *[see Warnings and Precautions (5.1)]*.**

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) *[see Warnings and Precautions (5.1)]*.[1]

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed **WARNING** at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.

LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike).

LUMASON is a registered trademark of Bracco Diagnostics Inc. SonoVue is a registered trademark of Bracco Suisse S.A.

Bracco Diagnostics Inc.
259 Prospect Plains Road, Building H
Monroe Township, NJ 08831 USA
Phone: 609-514-2200
Toll Free: 1-877-272-2269 (U.S. only)
Fax: 609-514-2446

©2019 Bracco Diagnostics Inc. All Rights Reserved.
16-030116A-U

BRACCO
LIFE FROM INSIDE